Diagnostic performance of F-18 fluorodeoxyglucose PET/computed tomography for diagnosis of polymyalgia rheumatica: a

Keunyoung Kim1, Seong-Jang Kim2,3,4

  • 1Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan.

Abstract

Insights

F-18 FDG PET/CT shows moderate diagnostic performance for polymyalgia rheumatic (PMR). Further multicenter studies are needed to confirm the accuracy of F-18 FDG PET/CT in detecting PMR.

Area of Science:

  • Nuclear Medicine
  • Diagnostic Imaging
  • Rheumatology

Background:

  • Polymyalgia rheumatic (PMR) is an inflammatory condition affecting older adults.
  • Accurate diagnosis of PMR is crucial for timely treatment and preventing complications.

Purpose of the Study:

  • To evaluate the diagnostic performance of F-18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) for diagnosing PMR.
  • To synthesize existing evidence through a meta-analysis.

Main Methods:

  • Systematic search of PubMed, Cochrane, and EMBASE databases up to February 29, 2020.
  • Meta-analysis of seven studies including 684 patients to assess diagnostic accuracy.
  • Calculation of pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratio.

Main Results:

  • Pooled sensitivity for F-18 FDG PET/CT in PMR diagnosis was 0.76 (95% CI, 0.67-0.83).
  • Pooled specificity was 0.87 (95% CI, 0.82-0.91).
  • Area under the hierarchical summary receiver operating characteristic curve was 0.93 (95% CI, 0.90-0.95).

Conclusions:

  • F-18 FDG PET/CT demonstrates moderate sensitivity and specificity for PMR diagnosis.
  • Current literature on F-18 FDG PET/CT for PMR is limited.
  • Larger multicenter studies are recommended to further validate its diagnostic accuracy.